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The aim of the study was to evaluate three serological methods for their ability to identify CF patients in different infection status especially
those at risk of developing chronic Pseudomonas aeruginosa (Pa) infection.
Methods: Two ELISA methods: exotoxin A (ExoA) and CF-IgG-ELISA (CF-IgG) and Crossed Immunoelectrophoresis (CIE) were used for
measurement of Pa-antibodies in sera from 791 Scandinavian CF patients.
Results: 381 patients were cultured negative for Pa in the year before study start, 129 patients were intermittently colonized and 281 patients were
chronically infected. The sensitivity of the investigated assays was 96%, 93% and 97%, specificity 89%, 89% and 83% for CIE, ExoA and CF-IgG
respectively. The negative predictive value was for CIE 97%, for ExoA 95% and for CF-IgG 98% and positive predictive values 87%, 86% and 80%.
Out of the 381 patients cultured negative for Pa, 11 changed status to chronically infected. Twenty-four out of the129 patients intermittently
colonized became chronically infected. The antibody levels in this latter group of patients were significantly higher already at the study start and
increased significantly during the study period (pb0.05). Elevated levels of specific anti-Pseudomonal antibodies showed to be the risk factor for
developing chronic P. aeruginosa infection (OR 4.9 and OR 2.7, pb0.05 for CF-IgG and ExoA).
Conclusion: All three serological assays were equally informative. The very high sensitivity of the assays made it possible to characterize patients with
different infection status. Elevated levels of specific anti-Pseudomonas antibodies showed to be the risk factor for developing chronic Pa infection. Due
to the specificity of the tests, antibiotic treatment based on serology might be considered in selected cases. There is a window of opportunity for
suppression and eradication of initial P. aeruginosa infection making measurement of specific anti-Pseudomonas antibodies helpful.
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Chronic pulmonary infection with P. aeruginosa develops in
most patients with cystic fibrosis (CF); by adulthood 80%
of patients are infected in most CF centers and chronic
P. aeruginosa infection is the primary cause of increased
morbidity and mortality in CF [1–5].
Chronic infection is, in most patients, preceded by a stage of
intermittent colonization for an average duration of 12 months
[6]. This initial stage is characteristically followed by the
gradual emergence of mucoid variants of the colonizing strains
and a rise in anti-Pseudomonas antibodies [7] and chronic
infection with exacerbations, limiting the life span of CF
patients [1,8]. To distinguish between intermittent colonization
and chronic infection is difficult, particularly in young, non-
sputum producing CF children [9–11]. Different serological
assays and type of antigens have been used to follow the course
of early colonization and infection with P. aeruginosa
[7,10,12,13–20]. Two recently published studies have shown
the diagnostic value of rising anti-Pseudomonas antibodies in
development of chronic infection [21,22]. Despite the growing
evidence of the diagnostic value of serum anti-Pseudomonas
antibody measurement, the usefulness of Pseudomonas
serology in CF children is still being questioned [23]. The
major problem in using the variety of published serological
tests in diagnosis of early P. aeruginosa infection is that only
few of them are commercially available and none of them have
been compared to each other. In the present study we evaluate
three different assays for measurement of anti-Pseudomonas
antibodies and their abilities to identify patients with already
established chronic infection as well patients at risk of
developing chronic P. aeruginosa infection.
2. Materials and methods
2.1. Patients
The Scandinavian CF Study Consortium (SCFSC) was
established in 1999. All eight CF-centres in Scandinavia
participated in the study. The total number of diagnosed CF
patients in the three countries was 1153 (Denmark 393,
Norway 240, Sweden 520) and 791 (69%) of patients for
whom both the microbiological data from the year before study
start and serum samples for serological investigation were
availably were included.
Patients were included consecutively from August 2001 to
June 2003 and were followed prospectively for a median of
371 days (range 280–497). The only exclusion criterion was
lung transplantation. Patients who underwent lung transplanta-
tion during the study period or died were excluded from the
follow-up study. Mean number of microbiological examina-
tions, per patient per year, ranged from 10 (Denmark), to 8
(Norway) and to 5 (Sweden). Pseudomonas aeruginosa
positivity was assessed mainly by sputum cultures. Bacteriolo-
gical cultures from non-sputum-producing patients were
obtained from the nasopharynx in Sweden while in Denmark
and Norway laryngeal aspirations were taken at every visit.Demographics, clinical data and P. aeruginosa colonization
status were recorded at inclusion and at the end of the study. For
sensitivity and specificity testing of the investigated methods
the first serum sample was used.
2.2. Definition of infection status regarding P. aeruginosa
Classification of each patient's P. aeruginosa infection status
at start and end of the study was based on the following criteria
(Leeds criteria) [24] relying on microbiological examinations at
least every 3rd month:
Chronic: more than 50% of the months in a one-year period
when samples had been taken being P. aeruginosa culture-
positive.
Intermittent: 50% or less of the months when samples had
been taken being P. aeruginosa culture-positive.
Free: no growth of P. aeruginosa for the previous 12 months.
Never: since only 12 months' microbiological data were
available, this group was not defined in the present study.
Antibody assays:
1. Crossed immunoelectrophoresis (CIE) [12] using
water-soluble antigens (St-Ag:1–17) from P. aerugi-
nosa strains representing the 17 serotypes of the
International Antigenic Typing Scheme which has
been used since 1972 in Denmark and is available at
Department of clinical microbiology, Rigshospitalet,
Copenhagen. St-Ag:1–17 contains at least 64 different
antigens [12]. Precipitins level equal or above 2 were
defined as elevated.
2. Exotoxin A ELISA (ExoA) [13,25] using exotoxin A
(0.75 µg/ml) is an assay routinely used in Sweden
since 1985 and available at the Karolinska University
Hospital, Stockholm. Antibody levels above 110
ELISA units (EU) for children younger than 4 years
and 160 for patients older than 4 years were defined as
elevated based on results from investigations on
healthy population (mean+2 SD). A value of 110 or
160 corresponds to 1 in relative ELISA units. All
results are expressed as relative ELISA units (REU) in
relation to cut off values.
3. Pseudomonas-CF-IgG ELISA (CF-IgG) [15,21] using
St-Ag:1–17 is the assay used in Copenhagen CF
centre together with CIE as a routine method for
measurement of specific anti-Pseudomonas antibo-
dies since 1996 and is now commercially available
from Statens Seruminstitut, Copenhagen, Denmark.
Normal values for the assay were established, based
on results from investigation on CF patient popula-
tion. Mean+1 SD was calculated from results of
evaluation of sera from healthy subjects and CF
patients without history of P. aeruginosa coloniza-
tion [21]. The cut off level 1.501 EU was given a
value of 1 and all results were expressed as a REU
in the relation to the cut off value. The diagnostic
performance of CF-IgG has recently been confirmed
[26].
Table 1
Demographic data on CF patients from three Scandinavian countries included in the study
Free of P. aeruginosa Intermittently colonized Chronically infected p
Number 381 129 281
Gender M/F 206/175 62/67 146/135 ns
Age; median (range) 12.4 (0.4–73.2) 12.4 (0.3–58.5) 26.5 (3–59.7) a pb0.05
Exotoxin A relative EU at inclusion; median (range) 0.32 (0.06–3.4) 0.66 (0.03–14.4) 3.02 (0.25–26.3) pb0.05
All groups
Pseudomonas-CF-IgG relative EU at inclusion; median (range) 0.44 (0.1–70.5) 0.74 (0.09–41) 35.2 (0.47–393.0) pb0.05
All groups
Precipitins (CIE); median of numbers (range) 0(0–36) 0(0–28) 24(0–53) pb0.05
All groups
FEV1 in % of predicted; median (range) 86.5 (16.5–132) 80.9 (19.7–129.0) 61.8
(16.1–148.5)
pb0.05
All groups
a Group with results statistically different from the two other groups.
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Confidence intervals of sensitivity and specificity were
calculated with Wilcoxon signed rank test for paired and
unpaired data. One-way ANOVAwas used to compare groups,
and differences between antibody levels at inclusion and at
completion were tested by paired-samples t test, respectively.
A stepwise logistic regression model was used to determine
risk factors for acquisition of chronic P. aeruginosa infection.
A p value≤0.05 was considered statistically significant. For
significant variables of stepwise logistic regression, the odds
ratio (OR) with 95% confidence intervals were calculated.
3. Results
Demographic data of the study population are given in
Table 1.
Microbiological data from one year before the study start
were available for all 791 CF patients. 381 patients had been
culture negative for P. aeruginosa, 129 patients were inter-
mittently colonized and 281 patients chronically infected
according to the Leeds definition. The non-colonized and
intermittently colonized patients were significantly younger
than the chronically infected patients (Table 1, pb0.05).
Specific anti-Pseudomonas antibody levels were significantly
different between the groups (Table 1, pb0.05). Also FEV1
differed significantly between the non-colonized and intermit-
tently colonized group despite no significant difference in age.Table 2
Specificity, sensitivity, positive and negative predicted value of anti-Pseudomonas a
Crossed immunoelectrophore
Specificity 89% [86–92]
Sensitivity 96% [93–98]
Positive/negative predictive value 87% [82–90]/97% [95–99]
Specificity after patients with other Gram-negative
infection were excluded
94% [91–96]
Sensitivity after patients with other Gram-negative
infection were excluded
97% [93–98]
Positive/negative predictive value after other
Gram-negative infection were excluded
93% [89–95]/97% [95–99]The sensitivity of all assays were very high; 96% for CIE,
97% for CF-IgG and 93% for ExoA ELISA and stayed
unchanged independent whether tested with only patients free
of P. aeruginosa or together with patients intermittently
infected. The specificity varied between 89%, 83% and 89%
for CIE, CF-IgG and ExoA ELISA respectively when patients
free of P. aeruginosa were tested and decreased to 86%, 78%
and 84% when intermittently infected patients were included.
When patients with other Gram-negative infection (Burkhol-
deria sp., Achromobacter xylosoxidans or Stenotrophomonas
maltophilia) than P. aeruginosa were excluded, the sensitivity
was unchanged but specificity improved, being 94%, 87% and
90% for CIE, CF-IgG and ExoA ELISA respectively (Table 2).
Both ELISA assays were tested for their ability to identify
patients at risk of developing chronic P. aeruginosa infection
during the one-year observation period.
Out of 381 patients cultured negative for P. aeruginosa 27
changed status to intermittent colonization and 11 to chronic
infection during the study period. Out of 129 patients
intermittently colonized 24 became chronically infected. The
antibody levels in the group of patients with change in infection
status to chronically infected from either non-colonized or
intermittently colonized, were significantly higher compared to
the group of patients with no change in infection status. This
was evident already at the study start and increased significantly
during the study period (Table 3, pb0.05). In contrast, in the
group of 448 patients who did not change their infection status
the levels of specific anti-Pseudomonas antibodies werentibody assays according to Leeds criteria of chronic infection
sis [CI] Pseudomonas-CF-IgG ELISA [CI] Exotoxin A ELISA [CI]
83% [78–87] 89% [85–92]
97% [94–99] 93% [89–96]
80% [75–84]/98% [95–99] 86% [81–90]/95% [92–97]
87% [82–90] 90% [86–93]
97% [93–99] 94% [90–96]
85% [80–89]/97% [94–99] 88% [84–92]/95% [92–97]
Table 3
Specific anti-Pseudomonas antibody levels in different groups of patients with CF according to infection status at start and at the end of the study
a)
Exotoxin A at start Exotoxin A at end p value
Median (range) REU Median(range) REU
Patients (both non- and intermittently colonized) who did
not change colonization/infection status. N=448
0.32 (0.03–3.9) 0.31 (0.03–4.7) Ns
Patients who changed colonization/infection status from
either non-colonized or intermittently colonized
to chronically infected. N=35
0.66 (0.19–5.8) 0.73 (0.19–4.3) Ns
Patients who changed colonization/infection status from
intermittently to chronically infected. N=24
1.14 (0.25–5.8) 1.5 (0.41–4.31) p=0.02 between values
at start and end
p value pb0.004 between patients who changed
colonization status and those who did not
b)
Pseudomonas-CF-IgG at start Pseudomonas-CF-IgG
at end
p value
Median (range) REU Median (range) REU
Patients (both non- and intermittently colonized) who did
not change colonization/infection status. N=448
0.41 (0.03–3.0) 0.47 (0.03–5.4) Ns
Patients who changed colonization/infection status from
either non-colonized or intermittently colonized
to chronically infected. N=35
1.06 (0.09–3.5) 1.21 (0.35–23.8) p=0.04 between values
at start and at end
Patients who changed colonization/infection status from
intermittently to chronically infected. N=24
1.03 (0.09–3.5) 1.32 (0.41–23.8) pb0.001 between values
at start and end
p value p=0.001 between patients who changed
colonization status and who did not
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became chronically infected during the study period had
elevated levels of anti-Pseudomonas antibodies measured by
ExoA ELISA and 17 of 35 (49%) of patients had elevated
levels of anti-Pseudomonas antibodies measured by CF-IgG
ELISA. In contrast, of patients not chronically infected with
P. aeruginosa and who did not become chronically infected
during the observation period only 15% (68) and 17% (79) had
elevated specific anti-Pseudomonas antibodies measured by
ExoA and CF-IgG ELISA respectively. Changes in antibody
levels in the group of patient free of P. aeruginosa who became
intermittently colonized were not significant.
Logistic regression analysis showed that the risk factor for
developing chronic P. aeruginosa infection was elevated levels
of specific anti-Pseudomonas antibodies measured by CF-IgG
ELISAwith OR 4.9 (95% CI 2.4–10, p=0.0001) and by ExoA
ELISA with OR 2.7 (95% CI 1.2–5.7, pb0.05).
4. Discussion
The primary objective of this study was to compare the
sensitivity and specificity of three serological methods for the
quantification of antibodies against P. aeruginosa and the
qualitative assessment of bacterial colonization status in CF
patients.
To our knowledge, this is the first study published that
compares different serological assays, one of them commer-
cially available, for their ability to detect and characterize
P. aeruginosa colonization status in a large CF population.The antibody response against P. aeruginosa in cystic
fibrosis is both a marker of chronic infection, inflammation and
of tissue damage [12]. Measurement of antibodies against
P. aeruginosa in patients with cystic fibrosis is therefore used in
some centers to distinguish between intermittent P. aeruginosa
colonization and chronic P. aeruginosa infection characterized
by a significant antibody response. The predictive values of
both a positive and a negative antibody test to discriminate
between intermittent colonization and chronic infection is about
90% [7,10,12,17].
This fact has important therapeutic consequences as it is
possible to prevent chronic P. aeruginosa infection in 80% of
patients by early aggressive antibiotic treatment of the intermittent
colonization [27]. Likewise, with aggressive suppressive anti-
biotic treatment of chronic P. aeruginosa infection it is possible to
maintain lung function for many years and to improve the
prognosis of patients with cystic fibrosis, although the infection is
virtually never eradicated [28].
The pioneering studies on P. aeruginosa serology were
published several decades ago showing their applicability to
diagnose chronic P. aeruginosa infection [12]. Since then a series
of publications confirm the usefulness of determining
P. aeruginosa specific antibody levels in classifying infection
status of patients with CF [1,18,21,26,29–31]. All three antibody
assays were evaluated in comparison with Leeds criteria, a
definition based on culture results alone. Our results, comparing
the three different serological assays showed a very high
sensitivity and specificity for all assays. However, some
differences in sensitivity and specificity as well as positive and
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may depend on the antigens used in the assays. In CF-IgG ELISA
and CIE, the water-soluble antigens from P. aeruginosa strains
representing 17 serotypes are used, in contrary to ExoA ELISA
using exotoxin A, a single P. aeruginosa antigen. Exotoxin A is a
quorum sensing regulated antigen like the P. aeruginosa enzymes
elastase and alkaline protease, implying that a high density of
bacteria is required before the genes responsible for the
production of these antigens are switched on [32,33]. It has also
been shown that antibodies to the quorum sensing regulated
elastase and alkaline protease develop several months later in CF
patients than those against St-Ag-1–17 [29].
Furthermore, immunization of rabbits with St-Ag has shown
that the antibody response is highly individual and that no single
antigen would be able to induce antibodies in all 10 rabbits
investigated [34].
When sputum cultures are used to determine CF patients'
infection status, the number of cultures available can be crucial for
the results achieved. In particular, the distinction between non-
colonized and intermittently colonized patients is very difficult as
these groups are most often not sputum producing. This can partly
explain the range in antibody levels and the lower positive
predicted values observed. In the present study, all patients
included in the bacteriological evaluation according to Leeds
criteria had on average eight sputum samples investigated. This
very high number of samples investigated contributed undoubt-
edly to the very good agreement between the results obtained.
Distribution between patients free of P. aeruginosa and
patients chronically infected differ between our and Leeds patient
population [24]. In our study 16% of the patients were defined as
intermittently infected, 48% free of P. aeruginosa and 36%
chronically infected. In the paper of Lee et al. 34% of patients
were intermittently infected, the group of free and never colonized
accounted for 48% and 18% were chronically infected. The
groups free of P. aeruginosa were very similar but the group of
chronically infected patients was larger in our study. The Leeds
population is much younger than ours. The chronically infected
patients were on average 13 years old in the Leeds population and
26 years old in ours. This makes it difficult to compare these
populations and probably can explain the differences observed.
Both ELISA assays were able to identify the patients at risk
of developing a chronic P. aeruginosa infection during the
study period. Elevated levels of specific antibodies measured by
ExoA and particularly by CF-IgG ELISA were risk factors for
developing a chronic P. aeruginosa infection.
The results show that antibody measurement has a potential
diagnostic value and can be used as a tool for identification of
the group of CF patients at risk of establishing chronic
P. aeruginosa infection. Especially increasing levels of specific
anti-Pseudomonas antibodies seem to be a useful parameter for
identifying the patients being at risk of developing a chronic
infection. For this reason, regular measurements of specific anti-
P. aeruginosa antibodies ought to be taken into consideration as
a part of follow up in all CF patients. Both ELISA assays have
shown the ability to distinguish between chronic infection and
intermittent colonization in the majority of cases. This is
important, since the clinician has to decide whether a CF patientwith P. aeruginosa positive sputum culture should be given
early aggressive eradication therapy to prevent chronic infection
or whether the patient should begin regular maintenance therapy
of chronic P. aeruginosa infection to prevent deterioration of
lung function [2,35]. Using a mix of antigens, cross-reactive
antibodies may occur, induced mainly by other Gram-negative
bacteria according to taxonomic relatedness. Absorption
experiments are therefore required in some cases [36,37].
Establishment of a reference laboratory for the measurement of
specific anti-Pseudomonas antibodies is probably a solution
for some of the problems in the diagnostic evaluation of the
Pseudomonas infection status in CF patients. This is a challenge
for future international collaboration.
In conclusion, all three serological assays are equally
informative. The very high sensitivity of the assays makes it
possible to characterize patients with negative antibody assays
as being free of chronic P. aeruginosa infection. Differentiation
between free and intermittent colonization with P. aeruginosa is
more difficult. The most interesting group is the group of
patients with negative or not available sputum samples that
shows increasing anti-Pseudomonas antibody levels. At the
current state of knowledge we generally do not recommend to
start treatment based solely on increased antibody levels but to
pursue diagnostics (such as verifying the pathogen by
bronchoscopy). On the other hand serology has been developed
to find pathogens in an early stage of infection. We have the
impression that due to the specificity of the tests antibiotic
treatment based on serology might be considered in selected
cases. There is a window of opportunity for suppression and
possible eradication of initial P. aeruginosa infection making
measurement of specific anti-Pseudomonas antibodies helpful.
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